financetom
Business
financetom
/
Business
/
PayPal's Q4 Non-GAAP Earnings, Net Revenue Increase; Q1, 2025 Outlook Issued
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PayPal's Q4 Non-GAAP Earnings, Net Revenue Increase; Q1, 2025 Outlook Issued
Feb 4, 2025 4:43 AM

07:19 AM EST, 02/04/2025 (MT Newswires) -- PayPal Holdings ( PYPL ) reported Q4 non-GAAP earnings Tuesday of $1.19 per diluted share, up from $1.14 a year earlier.

Analysts polled by FactSet expected $1.12.

Net revenue for the quarter ended Dec. 31 was $8.37 billion, compared with $8.03 billion a year earlier.

Analysts polled by FactSet expected $8.26 billion.

The company said it expects Q1 non-GAAP EPS of $1.15 to $1.17.

Analysts polled by FactSet expect $1.13.

PayPal ( PYPL ) said it expects 2025 non-GAAP EPS of $4.95 to $5.10.

Analysts polled by FactSet expect $4.90.

The company also said its board approved a new $15 billion share buyback program in addition to its 2022 repurchase authorization, which had remaining balance of $4.86 billion as of Dec. 31.

PayPal ( PYPL ) shares were down more than 6% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pharming Reports Positive Phase III Data on Leniolisib in Children With Rare Primary Immunodeficiency; Shares Rise
Pharming Reports Positive Phase III Data on Leniolisib in Children With Rare Primary Immunodeficiency; Shares Rise
Dec 11, 2024
11:00 AM EST, 12/11/2024 (MT Newswires) -- Pharming Group ( PHAR ) reported Wednesday positive phase III data for its investigational drug leniolisib in children aged between four and 11 years with activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency. The biopharmaceutical company said the data was consistent with improvements seen in a previously reported randomized controlled trial in...
Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis
Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis
Dec 11, 2024
11:02 AM EST, 12/11/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients. The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary...
BRIEF-Hershey's Main Owner Hershey Trust Rejects Mondelez's Offer As Too Low - Bloomberg News
BRIEF-Hershey's Main Owner Hershey Trust Rejects Mondelez's Offer As Too Low - Bloomberg News
Dec 11, 2024
Dec 11 (Reuters) - * HERSHEY'S MAIN OWNER HERSHEY TRUST REJECTS MONDELEZ'S OFFER AS TOO LOW - BLOOMBERG NEWS Source text: https://tinyurl.com/2accxuko ...
REUTERS NEXT-US bank executives expect Trump to ease rules, fuel growth
REUTERS NEXT-US bank executives expect Trump to ease rules, fuel growth
Dec 11, 2024
NEW YORK (Reuters) - President-elect Donald Trump is expected to adopt pro-growth policies that ease U.S. banking and credit card regulations, while spurring deals, industry executives said on a panel at the Reuters NEXT conference in New York on Wednesday. I hope the new administration will use this as a point to do a reset, Barclays U.S. consumer Bank CEO Denny Nealon...
Copyright 2023-2026 - www.financetom.com All Rights Reserved